#China #Shenzhen #SIBIONICS #AGP DTx Summit #DxTech

AGP & DTx Summit 2026: Transforming Diabetes Management

In May 2026, the 4th AGP & DTx Summit wrapped up successfully in Shenzhen, themed "Beyond Glucose". Co-organized by SIBIONICS, this prominent conference brought together international experts, healthcare providers, researchers, educators, and patient representatives to discuss how data from Continuous Glucose Monitoring (CGM) can extend beyond mere monitoring to create substantial clinical value.

The primary message throughout the event highlighted that CGM should not be viewed solely as a monitoring tool. Instead, its true value lies in translating glucose data into actionable clinical insights, treatment decisions, and notable behavioral changes.

During the International Consortium's progress report on AGP and DTx research advancements, Prof. Andrej Janež shared that the research fund financed 20 studies across 14 countries over the past two years. These studies predominantly focused on CGM and associated topics such as Continuous Ketone Monitoring (CKM), delving into aspects like accuracy among specific populations, dietary habits, glycemic response, AI-driven platforms, and clinical monitoring applications.

Prof. Sofianos Andrikopoulos reinforced the significance of Digital Therapeutics (DTx) in contemporary clinical practice. He elaborated that DTx encompasses software-based treatment, lifestyle guidelines, medication adherence support, and comprehensive care models. Presented data indicated an average HbA1c reduction of 0.54 percentage points associated with DTx usage, underscoring the role of these therapies in structured diabetes management.

From a clinical phenotype perspective, Prof. Wei Qiang demonstrated that integrating routine hospital admission measurements with CGM and AGP data could assist in identifying metabolic phenotypes and treatment responses in hospitalized type 2 diabetes patients, leading to more targeted and personalized healthcare.

Furthermore, Prof. Shannon Lin observed that the potential of CGM data may have reached its peak, emphasizing the necessity for data-driven treatments. Studies revealed a strong interest among clinicians and patients for integrating AI with CGM monitoring, as this technology aids in determining prognosis and providing personalized recommendations. Prof. Xiao Luo discussed her findings, which suggested that combining CGM with CKM monitoring could highlight glucose and ketone level changes during fasting and eating cycles, enhancing the effectiveness of metabolic interventions.

Patient representative Tom Vesely, who has lived with type 1 diabetes for nearly 40 years, reminded attendees that CGM makes daily fluctuations in glucose levels visible, emphasizing that the goal is not only to prolong time spent in targeted glycemic ranges but also to enhance psychological comfort—coined as "Time in Happiness."

Overall, the discussions at the summit indicate an evolving paradigm in diabetes care, transitioning from mere monitoring to active change, poised to improve the quality of life for individuals living with diabetes.